Over the past decade, the emergence of effective immunotherapies has revolutionized the
clinical management of many types of cancers. However, long-term durable tumour control …

Chimeric antigen receptor (CAR) T cell (CAR-T cell) therapy based on gene editing
technology represents a significant breakthrough in personalized immunotherapy for human …

Recent advances in neoantigen research have accelerated the development of tumor
immunotherapies, including adoptive cell therapies (ACTs), cancer vaccines and antibody …

In the past decade, the emergence of chimeric antigen receptor (CAR) T-cell therapy has led
to a cellular immunotherapy revolution against various cancers. Although CAR-T cell …

Excessive inflammation is the primary cause of mortality in patients with severe COVID-19,
yet the underlying mechanisms remain poorly understood. Our study reveals that ACE2 …

Simple Summary Chimeric antigen receptor (CAR)-T cell therapy has been highly
successful in treating hematological malignancies like leukemia and lymphoma, leading to …

Over the past decade, immunotherapy has emerged as one of the most promising
approaches to cancer treatment. The use of immune checkpoint inhibitors has resulted in …

Hepatocellular carcinoma (HCC) is the major subtype of liver cancer, which ranks sixth in
cancer incidence and third in mortality. Although great strides have been made in novel …

Breast cancer (BC) is the fourth most prevalent cancer in China. Despite conventional
treatment strategies, BC patients often have poor therapeutic outcomes, leading to …

T cell receptors (TCRs) recognize peptide antigens bound to major histocompatibility
complex (MHC) molecules (p/MHC) that are expressed on cell surfaces; while B cell-derived …